Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effects of Long-term Use of Proton Pump Inhibitors on Systemic Arterial Stiffness and Pulse Wave Velocity

Author(s): Ufuk Kutluana*, Ecem Kutluana, Mehmet Alpua and Mert Özen

Volume 20, Issue 5, 2022

Published on: 06 June, 2022

Page: [439 - 446] Pages: 8

DOI: 10.2174/1570161120666220407115457

Price: $65

Abstract

Background and Aim: Proton pump inhibitors (PPIs) are among the most widely prescribed agents. Although PPIs are widely regarded as harmlesss, long-term use of PPIs (LTUPPI) can have the potential to increase the risk of developing cardiovascular (CV) disease (CVD). Pulse wave velocity (PWV) is a good indicator of arterial stiffness. Several studies show a relationship between LTUPPI and CVD. However, the association between LTUPPI and PWV or arterial stiffness has not been reported.

Patients and Methods: Patients (n=64) with LTUPPI and controls (n=91) were included. PWV, glucose, creatinine, total cholesterol, triglyceride, low-density lipoprotein cholesterol, cholesterol, highdensity lipoprotein cholesterol, and magnesium levels were measured.

Results: In the LTUPPI group, PWV was greater than in controls (9.08±2.04 vs. 7.77±1.52 m/s, respectively, p=0.01); 34.4% of patients and 8.8% of controls had PWV levels >10 m/s (p=0.000). Multiple logistic regression analysis showed age (p<0.001) and LTUPPI (p=0.024) as predictors of elevated PWV.

Conclusion: PWV values are increased in patients with LTUPPI compared to controls independently of conventional CV risk factors. Measurement of PWV and other arterial stiffness parameters in cases with LTUPPI may be useful to predict possible CVD. Studies involving greater numbers are needed to confirm these findings.

Keywords: Proton pump inhibitors, cardiovascular disease, pulse wave velocity

« Previous Next »
[1]
Shi S, Klotz U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64(10): 935-51.
[http://dx.doi.org/10.1007/s00228-008-0538-y] [PMID: 18679668]
[2]
Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis 2006; 24(1-2): 11-46.
[http://dx.doi.org/10.1159/000091298] [PMID: 16699262]
[3]
Ren D, Gurney E, Hornecker J. Appropriate use and stewardship of proton-pump inhibitors. US Pharm 2019; 44: 25-31.
[4]
Metz DC. Long-term use of proton pump inhibitor therapy. Gastroenterol Hepatol (N Y) 2008; 4(5): 322-5.
[PMID: 21904505]
[5]
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42(6): 649-63.
[http://dx.doi.org/10.1111/apt.13324] [PMID: 26177572]
[6]
Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol 2018; 15(4): 230-40.
[http://dx.doi.org/10.1038/nrcardio.2017.154] [PMID: 29022571]
[7]
Shih CJ, Chen YT, Ou SM, et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014; 177(1): 292-7.
[8]
Juurlink DN, Dormuth CR, Huang A, et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One 2013; 8(12): e84890.
[9]
Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? Eur J Intern Med 2020; 72: 15-26.
[http://dx.doi.org/10.1016/j.ejim.2019.11.017] [PMID: 31796246]
[10]
Corsonello A, Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends Cardiovasc Med 2019; 29(6): 353-60.
[http://dx.doi.org/10.1016/j.tcm.2018.10.008] [PMID: 30389278]
[11]
Sukhovershin RA, Cooke JP. How may proton pump inhibitors impair cardiovascular health? Am J Cardiovasc Drugs 2016; 16(3): 153-61.
[http://dx.doi.org/10.1007/s40256-016-0160-9] [PMID: 26817947]
[12]
Kheloufi F, Frankel D, Kaspi E, et al. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. Therapie 2018; 73(3): 273-81.
[http://dx.doi.org/10.1016/j.therap.2017.08.003] [PMID: 29128115]
[13]
Mitchell GF. Arterial stiffness and wave reflection: Biomarkers of cardiovascular risk. Artery Res 2009; 3(2): 56-64.
[http://dx.doi.org/10.1016/j.artres.2009.02.002] [PMID: 20161241]
[14]
Wilkinson IB, Mäki-Petäjä KM, Mitchell GF. Uses of arterial stiffness in clinical practice. Arterioscler Thromb Vasc Biol 2020; 40(5): 1063-7.
[http://dx.doi.org/10.1161/ATVBAHA.120.313130] [PMID: 32102569]
[15]
Loehr LR, Meyer ML, Poon AK, et al. Prediabetes and diabetes are associated with arterial stiffness in older adults: The ARIC study. Am J Hypertens 2016; 29(9): 1038-45.
[http://dx.doi.org/10.1093/ajh/hpw036] [PMID: 27068705]
[16]
Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: A nationwide cohort study. Ann Intern Med 2010; 153(6): 378-86.
[http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00005] [PMID: 20855802]
[17]
Marlicz W, Koulaouzidis A, Loniewski I, Koulaouzidis G. Proton pump inhibitors accelerate endothelial senescence. Circ Res 2016; 119(2): e31-2.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309157] [PMID: 27390341]
[18]
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20(10): 1161-81.
[http://dx.doi.org/10.1097/00000478-199610000-00001] [PMID: 8827022]
[19]
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499] [PMID: 4337382]
[20]
Wassertheurer S, Kropf J, Weber T, et al. A new oscillometric method for pulse wave analysis: Comparison with a common tonometric method. J Hum Hypertens 2010; 24(8): 498-504.
[http://dx.doi.org/10.1038/jhh.2010.27] [PMID: 20237499]
[21]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-357.
[http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc] [PMID: 23817082]
[22]
Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand name and generic proton pump inhibitor prescriptions in the United States: Insights from the national ambulatory medical care survey (2006-2010). Gastroenterol Res Pract 2015; 2015: 689531.
[http://dx.doi.org/10.1155/2015/689531] [PMID: 25733976]
[23]
Granero-Melcon B, Morrás I, Galán-DeJuana M, Abad-Santos F. Appropriateness of the use of proton pump inhibitors in the Emergency Department of a Spanish university hospital. Rev Esp Enferm Dig 2018; 110(12): 755-61.
[http://dx.doi.org/10.17235/reed.2018.5468/2018] [PMID: 30362359]
[24]
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the american gastroenterological association. Gastroenterology 2017; 152(4): 706-15.
[http://dx.doi.org/10.1053/j.gastro.2017.01.031] [PMID: 28257716]
[25]
Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128(8): 845-53.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003602] [PMID: 23825361]
[26]
Surdacki A, Nessler J. Asymmetric dimethylarginine versus proton pump inhibitors usage in patients with stable coronary artery disease: A cross-sectional study. Int J Mol Sci 2016; 17(4): 454.
[27]
Ghebremariam YT, Cooke JP, Khan F, et al. Proton pump inhibitors and vascular function: A prospective cross-over pilot study. Vasc Med 2015; 20(4): 309-16.
[http://dx.doi.org/10.1177/1358863X14568444] [PMID: 25835348]
[28]
Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355(17): 1834-6.
[http://dx.doi.org/10.1056/NEJMc066308] [PMID: 17065651]
[29]
Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: A clinical case series. QJM 2010; 103(6): 387-95.
[http://dx.doi.org/10.1093/qjmed/hcq021] [PMID: 20378675]
[30]
McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104(2) (Suppl. 2): S5-9.
[PMID: 19262546]
[31]
Kyrtopoulos SA. Ascorbic acid and the formation of N-nitroso compounds: Possible role of ascorbic acid in cancer prevention. Am J Clin Nutr 1987; 45(5) (Suppl.): 1344-50.
[http://dx.doi.org/10.1093/ajcn/45.5.1344] [PMID: 3578122]
[32]
Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation 2003; 108(8): 933-8.
[http://dx.doi.org/10.1161/01.CIR.0000085067.55901.89] [PMID: 12912818]
[33]
Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005; 10(1) (Suppl. 1): S27-33.
[http://dx.doi.org/10.1177/1358836X0501000105] [PMID: 16444866]
[34]
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug Saf 2014; 37(4): 201-11.
[http://dx.doi.org/10.1007/s40264-014-0144-0] [PMID: 24550106]
[35]
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363(20): 1909-17.
[http://dx.doi.org/10.1056/NEJMoa1007964] [PMID: 20925534]
[36]
Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180(7): 713-8.
[http://dx.doi.org/10.1503/cmaj.082001] [PMID: 19176635]
[37]
Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25(5): 932-43.
[http://dx.doi.org/10.1161/01.ATV.0000160548.78317.29] [PMID: 15731494]
[38]
Kawai T, Ohishi M, Onishi M, et al. Cut-off value of brachial-ankle pulse wave velocity to predict cardiovascular disease in hypertensive patients: A cohort study. J Atheroscler Thromb 2013; 20(4): 391-400.
[http://dx.doi.org/10.5551/jat.15040] [PMID: 23268984]
[39]
Nunan D, Fleming S, Hametner B, Wassertheurer S. Performance of pulse wave velocity measured using a brachial cuff in a community setting. Blood Press Monit 2014; 19(6): 315-9.
[http://dx.doi.org/10.1097/MBP.0000000000000066] [PMID: 25000541]
[40]
Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T. Oscillometric estimation of aortic pulse wave velocity: Comparison with intra-aortic catheter measurements. Blood Press Monit 2013; 18(3): 173-6.
[http://dx.doi.org/10.1097/MBP.0b013e3283614168] [PMID: 23571229]
[41]
Korkmaz H, Sahin F, Ipekci SH, Temel T, Kebapcilar L. Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2014; 26(7): 725-32.
[http://dx.doi.org/10.1097/MEG.0000000000000104] [PMID: 24901818]
[42]
Korkmaz H, Sozen M, Kebapcilar L. Increased arterial stiffness and its relationship with inflammation, insulin, and insulin resistance in celiac disease. Eur J Gastroenterol Hepatol 2015; 27(10): 1193-9.
[http://dx.doi.org/10.1097/MEG.0000000000000437] [PMID: 26181110]
[43]
Kutluana U, Kilciler AG. Is there a possible relationship between gastric intestinal metaplasia and systemic arterial stiffness? Rev Esp Enferm Dig 2019; 111(7): 500-6.
[http://dx.doi.org/10.17235/reed.2019.5945/2018] [PMID: 31081669]
[44]
Zilberman JM. [Menopause: Hypertension and vascular disease]. Hipertens Riesgo Vasc 2018; 35(2): 77-83.
[http://dx.doi.org/10.1016/j.hipert.2017.11.001] [PMID: 29396243]
[45]
Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71(5): 437-9.
[http://dx.doi.org/10.1136/hrt.71.5.437] [PMID: 8011406]
[46]
Osawa H, Kawakami M, Fujii M, et al. Helicobacter pylori infection and coronary heart disease in Japanese patients. Cardiology 2001; 95(1): 14-9.
[http://dx.doi.org/10.1159/000047337] [PMID: 11385186]
[47]
Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311(7007): 711-4.
[http://dx.doi.org/10.1136/bmj.311.7007.711] [PMID: 7549683]
[48]
Torisu T, Takata Y, Ansai T, et al. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. J Atheroscler Thromb 2009; 16(5): 691-7.
[http://dx.doi.org/10.5551/jat.943] [PMID: 19729867]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy